MapLight Therapeutics (MPLT) Stock Overview
Operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
MPLT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
MapLight Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.21 |
| 52 Week High | US$40.43 |
| 52 Week Low | US$9.10 |
| Beta | 0 |
| 1 Month Change | -69.34% |
| 3 Month Change | -61.95% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| MPLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.3% | 6.3% | -1.2% |
| 1Y | n/a | 47.2% | 18.3% |
Return vs Industry: Insufficient data to determine how MPLT performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MPLT performed against the US Market.
Price Volatility
| MPLT volatility | |
|---|---|
| MPLT Average Weekly Movement | 24.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MPLT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MPLT's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 133 | Chris Kroeger | www.maplightrx.com |
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
MapLight Therapeutics, Inc. Fundamentals Summary
| MPLT fundamental statistics | |
|---|---|
| Market cap | US$519.90m |
| Earnings (TTM) | -US$229.83m |
| Revenue (TTM) | n/a |
Is MPLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MPLT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$229.83m |
| Earnings | -US$229.83m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MPLT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/24 08:17 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MapLight Therapeutics, Inc. is covered by 14 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Malcolm Hoffman | BMO Capital Markets Equity Research |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Adam Vogel | Craig-Hallum Capital Group LLC |